CN101011543A - 一种新的抗肿瘤药物组合物 - Google Patents
一种新的抗肿瘤药物组合物 Download PDFInfo
- Publication number
- CN101011543A CN101011543A CNA2006101726247A CN200610172624A CN101011543A CN 101011543 A CN101011543 A CN 101011543A CN A2006101726247 A CNA2006101726247 A CN A2006101726247A CN 200610172624 A CN200610172624 A CN 200610172624A CN 101011543 A CN101011543 A CN 101011543A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- semen coicis
- cantharidin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 230000000118 anti-neoplastic effect Effects 0.000 title claims abstract description 5
- 239000003814 drug Substances 0.000 title claims description 62
- 241000208340 Araliaceae Species 0.000 claims abstract description 247
- 235000008434 ginseng Nutrition 0.000 claims abstract description 247
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 246
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 246
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims abstract description 67
- 229940095758 cantharidin Drugs 0.000 claims abstract description 62
- 229930008397 cantharidin Natural products 0.000 claims abstract description 62
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- 150000004676 glycans Chemical class 0.000 claims description 169
- 229920001282 polysaccharide Polymers 0.000 claims description 168
- 235000017709 saponins Nutrition 0.000 claims description 166
- 239000005017 polysaccharide Substances 0.000 claims description 161
- 150000007949 saponins Chemical class 0.000 claims description 157
- 210000000582 semen Anatomy 0.000 claims description 150
- 239000003921 oil Substances 0.000 claims description 149
- 229930182490 saponin Natural products 0.000 claims description 148
- 239000009636 Huang Qi Substances 0.000 claims description 129
- 238000002360 preparation method Methods 0.000 claims description 96
- 235000006533 astragalus Nutrition 0.000 claims description 93
- 241001061264 Astragalus Species 0.000 claims description 90
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 claims description 90
- 210000004233 talus Anatomy 0.000 claims description 84
- 239000000284 extract Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 32
- 229930182494 ginsenoside Natural products 0.000 claims description 28
- 229940089161 ginsenoside Drugs 0.000 claims description 28
- 241000545442 Radix Species 0.000 claims description 18
- 239000000890 drug combination Substances 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 15
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 14
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 5
- WUQNOBSCYAIJIH-FIPCFZRWSA-N (3as,4r,7s,7ar)-2,3a,7a-trimethyl-4,5,6,7-tetrahydro-octahydro-1h-4,7-epoxyisoindole-1,3-dione Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)N(C)C2=O WUQNOBSCYAIJIH-FIPCFZRWSA-N 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 4
- UCMLAGLRLOPBAX-PRRDBKRISA-N (3as,4r,7s,7ar)-3a,7a-dimethyl-2-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-4,5,6,7-tetrahydro-octahydro-1h-4,7-epoxyisoindole-1,3-dione Chemical compound C1=C(OC(F)(F)F)C=C2SC(N3C(=O)[C@]4(C)[C@H]5CC[C@H](O5)[C@@]4(C3=O)C)=NC2=C1 UCMLAGLRLOPBAX-PRRDBKRISA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 5
- 230000008569 process Effects 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 7
- 235000020710 ginseng extract Nutrition 0.000 abstract description 4
- 244000077995 Coix lacryma jobi Species 0.000 abstract description 3
- 229940107666 astragalus root Drugs 0.000 abstract description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 2
- 229940047169 astragalus root extract Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 136
- 235000019198 oils Nutrition 0.000 description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 127
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 105
- 239000000243 solution Substances 0.000 description 81
- 241000699670 Mus sp. Species 0.000 description 79
- 239000007924 injection Substances 0.000 description 79
- 238000002347 injection Methods 0.000 description 79
- 206010028980 Neoplasm Diseases 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 40
- 229960004756 ethanol Drugs 0.000 description 37
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 35
- 229940083466 soybean lecithin Drugs 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 239000008215 water for injection Substances 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 29
- 229920001214 Polysorbate 60 Polymers 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 28
- 239000007788 liquid Substances 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 238000012360 testing method Methods 0.000 description 27
- 210000003462 vein Anatomy 0.000 description 26
- 239000008187 granular material Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 210000000481 breast Anatomy 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 20
- 239000013558 reference substance Substances 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 229960004397 cyclophosphamide Drugs 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 17
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 15
- 238000005303 weighing Methods 0.000 description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 14
- 239000008108 microcrystalline cellulose Substances 0.000 description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 239000008227 sterile water for injection Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 12
- 238000004321 preservation Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 238000001291 vacuum drying Methods 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000002131 composite material Substances 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000007689 inspection Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 150000004804 polysaccharides Polymers 0.000 description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 239000011265 semifinished product Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 238000012869 ethanol precipitation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- -1 reflux Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 229940023488 pill Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- RSJOBNMOMQFPKQ-ZVGUSBNCSA-L copper;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O RSJOBNMOMQFPKQ-ZVGUSBNCSA-L 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000013505 freshwater Substances 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000045403 Astragalus propinquus Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 230000000274 adsorptive effect Effects 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 240000001592 Amaranthus caudatus Species 0.000 description 2
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004178 amaranth Substances 0.000 description 2
- 235000012735 amaranth Nutrition 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 229950005162 benexate Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- LMYVDPWHMJXPIY-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanol Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCO LMYVDPWHMJXPIY-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000131283 Cantharis Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001481669 Meloidae Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- 241001572617 Mylabris cichorii Species 0.000 description 1
- 241001572616 Mylabris phalerata Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- YEZWWUMWIFKEQM-UHFFFAOYSA-N O.OC.ClC(Cl)Cl.CCOC(C)=O Chemical compound O.OC.ClC(Cl)Cl.CCOC(C)=O YEZWWUMWIFKEQM-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 重量配比 | 给药剂量 | 瘤质量(g) | 抑瘤率(%) |
模型对照组 | - | - | 1.32±0.15 | - |
斑蝥素组 | - | 5mg | 0.95±0.14* | 28.03±0.07 |
人参组 | - | 0.5g | 0.84±0.13* | 36.37±0.13 |
黄芪组 | - | 0.5g | 0.92±0.14* | 30.30±0.07 |
1∶10∶10 | 0.5g | 0.78±0.13** | 40.91±0.13 | |
1∶4∶40 | 0.5g | 0.73±0.12** | 44.70±0.20 | |
1∶2∶100 | 0.5g | 0.69±0.12** | 47.73±0.20 | |
2∶5∶100 | 0.5g | 0.61±0.11** | 53.79±0.27 | |
1∶2∶20 | 0.5g | 0.54±0.11** | 59.10±0.27 | |
1∶2∶10 | 0.5g | 0.46±0.10** | 65.15±0.33 | |
1∶2∶5 | 0.5g | 0.40±0.09** | 69.70±0.40 | |
BSS组(斑蝥素、人参、黄芪的不同重量配比组) | 1∶1∶1 | 0.5g | 0.36±0.07** | 72.73±0.53 |
1∶2∶1 | 0.5g | 0.37±0.07** | 71.97±0.53 | |
1∶5∶1 | 0.5g | 0.41±0.10** | 68.94±0.33 | |
2∶10∶1 | 0.5g | 0.48±0.11** | 63.24±0.27 | |
2∶20∶1 | 0.5g | 0.56±0.12** | 57.58±0.20 | |
5∶40∶1 | 0.5g | 0.62±0.13** | 53.03±0.13 | |
15∶10∶1 | 0.5g | 0.68±0.13** | 48.49±0.13 | |
20∶200∶1 | 0.5g | 0.73±0.12** | 44.70±0.20 | |
1∶8∶4 | 0.5g | 0.77±0.14** | 41.67±0.07 |
组别 | 重量配比 | 给药剂量(g) | 瘤质量(g) | 抑瘤率(%) |
生理盐水组 | - | - | 1.78±0.31 | - |
薏苡仁油组 | - | 1 | 1.41±0.24* | 20.79±0.23 |
人参组 | - | 0.5 | 1.23±0.22* | 30.90±0.29 |
黄芪组 | - | 0.5 | 1.35±0.23* | 24.16±0.26 |
30∶1∶100 | 0.5 | 1.02±0.17** | 42.70±0.45 | |
40∶1∶50 | 0.5 | 0.95±0.16** | 44.94±0.48 | |
20∶1∶20 | 0.5 | 0.89±0.16** | 50.00±0.48 | |
10∶1∶10 | 0.5 | 0.81±0.15** | 56.50±0.52 | |
20∶1∶5 | 0.5 | 0.69±0.14** | 60.43±0.55 | |
YSS组(薏苡仁油、黄芪、人参的不同重量配比组) | 20∶2∶5 | 0.5 | 0.63±0.13** | 62.36±0.58 |
4∶1∶1 | 0.5 | 0.57±0.12** | 67.98±0.61 | |
4∶2∶1 | 0.5 | 0.56±0.13** | 68.54±0.58 | |
20∶5∶1 | 0.5 | 0.64±0.14** | 64.04±0.55 | |
30∶10∶1 | 0.5 | 0.76±0.15** | 57.30±0.52 | |
40∶20∶1 | 0.5 | 0.83±0.16** | 53.37±0.48 | |
100∶40∶1 | 0.5 | 0.91±0.17** | 48.88±0.45 | |
100∶100∶1 | 0.5 | 1.00±0.17** | 43.82±0.45 | |
100∶200∶1 | 0.5 | 1.06±0.18** | 40.45±0.42 |
组别 | 重量配比 | 给药剂量(mg/kg) | 瘤体重量(g) | 抑瘤率(%) |
生理盐水组去甲斑蝥素组薏苡仁油组人参多糖组人参总皂苷组黄芪总皂苷组黄芪多糖组 | - | - | 2.43±3.24 | - |
- | 2 | 1.54±3.38** | 36.63** | |
- | 4000 | 1.51±3.42** | 37.86** | |
- | 500 | 1.86±3.21* | 23.46* | |
- | 500 | 1.84±3.16* | 24.28* | |
- | 500 | 1.85±2.98* | 23.87* | |
- | 500 | 1.88±3.02* | 22.63* | |
QYRH I组(去甲斑蝥素+薏苡仁油+人参多糖+黄芪多糖) | 1∶100∶1∶10 | 100 | 1.30±2.75**abce | 46.09**abce |
1∶100∶5∶10 | 100 | 1.30±2.69**abce | 45.68**abce | |
1∶20∶4∶10 | 100 | 1.29±2.66**abce | 46.91**abce | |
1∶20∶5∶10 | 100 | 1.12+2.51**abce | 53.91**abce | |
1∶40∶5∶5 | 100 | 1.25±2.48**abce | 48.56**abce | |
1∶10∶5∶1 | 100 | 1.26±2.45**abce | 48.15**abce | |
2∶20∶5∶5 | 100 | 1.09±2.51**abce | 55.14**abce | |
1∶40∶2∶2 | 100 | 1.26±2.47**abce | 48.15**abce | |
2∶10∶1∶2 | 100 | 1.28±2.32**abce | 47.33**abce | |
10∶40∶1∶5 | 100 | 1.27±2.62**abce | 47.74**abce | |
QYRHII组(去甲斑蝥素+薏苡仁油+人参多糖+黄芪总皂苷) | 1∶100∶1∶10 | 100 | 1.32±2.75**abcf | 45.68**abcf |
1∶100∶5∶10 | 100 | 1.30±2.68**abcf | 46.50**abcf | |
1∶20∶4∶10 | 100 | 1.27±2.59**abcf | 47.74**abcf | |
1∶20∶5∶10 | 100 | 1.13±2.51**abcf | 53.50**abcf | |
1∶40∶5∶5 | 100 | 1.26±2.53**abcf | 48.15**abcf | |
1∶10∶5∶1 | 100 | 1.25±2.42**abcf | 48.56**abcf | |
2∶20∶5∶5 | 100 | 1.07±2.37**abcf | 55.97**abcf |
1∶40∶2∶2 | 100 | 1.27±2.40**abcf | 47.74**abcf | |
2∶10∶1∶2 | 100 | 1.28±2.41**abcf | 47.33**abcf | |
10∶40∶1∶5 | 100 | 1.29±2.52**abcf | 46.91**abcf | |
QYRHIII组(去甲斑蝥素+薏苡仁油+人参总皂苷+黄芪多糖) | 1∶100∶1∶10 | 100 | 1.29±2.63**abde | 46.91**abde |
1∶100∶5∶10 | 100 | 1.30±2.58**abde | 46.09**abde | |
1∶20∶4∶10 | 100 | 1.26±2.60**abde | 48.15**abde | |
1∶20∶5∶10 | 100 | 1.10±2.64**abde | 54.32**abde | |
1∶40∶5∶5 | 100 | 1.27+2.56**abde | 47.74**abde | |
1∶10∶5∶1 | 100 | 1.28±2.54**abde | 47.33**abde | |
2∶20∶5∶5 | 100 | 0.99+2.47**abde | 59.26**abde | |
1∶40∶2∶2 | 100 | 1.28±2.53**abde | 47.33**abde | |
2∶10∶1∶2 | 100 | 1.25±2.46**abde | 48.56**abde | |
10∶40∶1∶5 | 100 | 1.23±2.49**abde | 49.38**abde | |
QYRHIV组(去甲斑蝥素+薏苡仁油+人参总皂苷+黄芪总皂苷) | 1∶100∶1∶10 | 100 | 1.30±2.55**abdf | 45.27**abdf |
1∶100∶5∶10 | 100 | 1.29±2.52**abdf | 45.68**abdf | |
1∶20∶4∶10 | 100 | 1.27±2.49**abdf | 47.74**abdf | |
1∶20∶5∶10 | 100 | 1.04±2.47**abdf | 57.20**abdf | |
1∶40∶5∶5 | 100 | 1.26+2.46**abbf | 48.15**abdf | |
1∶10∶5∶1 | 100 | 1.25±2.39**abdf | 48.56**abdf | |
2∶20∶5∶5 | 100 | 1.03±2.35**abdf | 57.61**abdf | |
1∶40∶2∶2 | 100 | 1.26±2.61**abdf | 48.15**abdf | |
2∶10∶1∶2 | 100 | 1.24±2.57**abdf | 48.97**abdff | |
10∶40∶1∶5 | 100 | 1.25±2.52**abdf | 48.56**abdf |
组别 | 给药剂量(mg/kg) | 生存天数(d) | 生命延长率(%) |
生理盐水对照组 | 2ml | 11.6±3.6 | - |
去甲斑蝥素组 | 2 | 15.8±3.4* | 36.21 |
薏苡仁油组 | 4000 | 15.9±3.5* | 37.07 |
QYRHI组低剂量组 | 50 | 16.7±3.3*ab | 43.97*ab |
QYRHI组中剂量组 | 100 | 17.8±3.1**ab | 53.45**ab |
QYRHI组高剂量组 | 150 | 18.8±2.9**ab | 62.07**ab |
QYRHII组低剂量组 | 50 | 16.3±3.2*ab | 40.52*ab |
QYRHII组中剂量组 | 100 | 17.5±2.8**ab | 50.86**ab |
QYRHII组高剂量组 | 150 | 18.2±2.9**ab | 56.90**ab |
QYRHIII组低剂量组 | 50 | 16.4±3.5*ab | 41.38*ab |
QYRHIII组中剂量组 | 100 | 17.9±3.4**ab | 54.31**ab |
QYRHIII组高剂量组 | 150 | 18.5±3.1**ab | 59.48**ab |
QYRHIV组低剂量组 | 50 | 16.2±3.4*ab | 39.66*ab |
QYRHIV组中剂量组 | 100 | 17.7±2.8**ab | 52.59**ab |
QYRHIV组高剂量组 | 150 | 18.6±2.5**ab | 60.34**ab |
组别 | 治疗 | 平均瘤重(g) | 抑瘤率(%) | 增效率(%) |
空白对照组 | - | 2.3 1±0.62 | - | - |
60Co照射组 | 0.05Gy/min | 1.76±0.51* | 23.81* | - |
60Co照射+去甲斑蝥素组 | 0.05Gy+2mg/kg | 1.41±0.54* | 38.96*# | 19.89*# |
60Co照射+薏苡仁油组 | 0.05Gy+4g/kg | 1.46±0.56* | 36.80*# | 17.05*# |
60Co照射+QYRHI组低剂量组 | 0.05Gy+50mg/kg | 1.35±0.47**#ab | 41.56**#ab | 23.30**#ab |
60Co照射+QYRHI组中剂量组 | 0.05Gy+100mg/kg | 1.21±0.38**#ab | 47.62**#ab | 31.25**#ab |
60Co照射+QYRHI组高剂量组 | 0.05Gy+150mg/kg | 1.14±0.31**#ab | 50.65**#ab | 35.23**#ab |
60Co照射+QYRHII组低剂量组 | 0.05Gy+50mg/kg | 1.28±0.49**#ab | 44.59**#ab | 27.27**#ab |
60Co照射+QYRHII组中剂量组 | 0.05Gy+100mg/kg | 1.15±0.41**#ab | 50.22**#ab | 34.66**#ab |
60Co照射+QYRHII组高剂量组 | 0.05Gy+150mg/kg | 1.04±0.33**#ab | 54.98**#ab | 40.91**#ab |
60Co照射+QYRHIII组低剂量组 | 0.05Gy+50mg/kg | 1.29±0.50**#ab | 44.16**#ab | 26.70**#ab |
60Co照射+QYRHIII组中剂量组 | 0.05Gy+100mg/kg | 1.22±0.39**#ab | 47.19**#ab | 30.68**#ab |
60Co照射+QYRHIII组高剂量组 | 0.05Gy+150mg/kg | 1.08±0.32**#ab | 53.25**#ab | 38.64**#ab |
60Co照射+QYRHIV组低剂量组 | 0.05Gy+50mg/kg | 1.34±0.47**#ab | 41.99**#ab | 23.86**#ab |
60Co照射+QYRHIV组中剂量组 | 0.05Gy+100mg/kg | 1.21±0.36**#ab | 47.62**#ab | 31.25**#ab |
60Co照射+QYRHIV组高剂量组 | 0.05Gy+150mg/kg | 1.13±0.29**#ab | 51.08**#ab | 35.80**#ab |
组别 | 给药剂量(mg/kg) | 平均瘤重(g) | 抑瘤率(%) | 增效率(%) | WBC(×109) | 胸腺指数 | 脾指数 | |
空白对照组 | - | 2.28±1.36 | - | - | 8.56±2.2 1 | 27.19±6.08 | 26.26±4.94 | |
环磷酰胺组 | 30 | 1.33±1.27* | 41.67* | - | 3.32±1.62 | 13.25±4.73 | 14.59±2.64 | |
H+Q组 | 30+2 | 1.16±1.21**# | 49.12**# | 12.78*# | 4.67±1.58# | 1 5.43±5.23# | 16.88±3.42# | |
H+Y组 | 30+4000 | 1.17±1.25**# | 48.68**# | 12.03*# | 4.73±1.57# | 15.21±5.31# | 17.02±3.54# | |
H+QYRHI组 | 低 | 30+50 | 1.01±1.20**#ab | 55.70**#ab | 21.37**#ab | 5.62±1.53##ab | 17.07±4.49##ab | 17.72±3.24##ab |
中 | 30+100 | 0.83±1.11**#ab | 63.60**#ab | 35.11**#ab | 7.34±1.58##ab | 20.21±4.78##ab | 19.02±3.61##ab | |
高 | 30+150 | 0.52±1.06**#ab | 77.19**#ab | 56.49**#ab | 7.99±1.68##ab | 23.06±4.49##ab | 21.42±4.36##ab | |
H+QYRHII组 | 低 | 30+50 | 1.02±1.18**#ab | 55.26**#ab | 23.31**#ab | 6.56±1.48##ab | 16.89±4.37##ab | 17.81±3.18##ab |
中 | 30+100 | 0.82±1.12**#ab | 63.16**#ab | 36.84**#ab | 7.41±1.57##ab | 19.88±4.61##ab | 19.23±3.54##ab | |
高 | 30+150 | 0.54±0.99**#ab | 76.32**#abb | 59.40**#ab | 7.81±1.62##ab | 23.02±4.97##ab | 20.98±4.61##ab | |
H+QYRHIII组 | 低 | 30+50 | 0.99±1.20**#ab | 56.58**#ab | 25.56**#ab | 6.63±1.49##ab | 16.93±4.31##ab | 17.91±3.20##ab |
中 | 30+100 | 0.81±1.09**#ab | 64.47**#ab | 39.10**#ab | 7.48±1.60##ab | 19.97±4.76##ab | 19.17±3.62##ab | |
高 | 30+150 | 0.52±1.03**#ab | 77.19**#ab | 60.90**#ab | 7.86±1.69##ab | 22.78±14.59##ab | 21.64±4.43##ab | |
H+QYRHIV组 | 低 | 30+50 | 1.05±1.15**#ab | 53.95**#ab | 21.05**#ab | 6.59±1.47##ab | 16.82±4.27##ab | 17.69±3.12##ab |
中 | 30+100 | 0.86±1.01**#ab | 62.28**#ab | 35.34**#ab | 7.58±1.56##ab | 19.85±14.56##ab | 19.28±3.55##ab | |
高 | 30+150 | 0.59±0.87**#ab | 74.12**#ab | 55.64**#ab | 7.76±1.49##ab | 22.54±4.32##ab | 21.54±4.32##ab |
批号 | 人参多糖含量(%) | 得率(%) |
1 | 87.51 | 1.03 |
2 | 89.63 | 1.14 |
3 | 91.54 | 1.28 |
平均 | 89.56 | 1.15 |
批号 | 人参总皂苷含量(%) | 人参皂苷Re、人参皂苷Rg1含量(%) | 得率(%) |
1 | 71.54 | 36.25 | 1.16 |
2 | 66.34 | 35.41 | 1.01 |
3 | 74.51 | 38.79 | 1.18 |
平均 | 70.80 | 36.82 | 1.12 |
批号 | 黄芪多糖含量(%) | 得率(%) |
1 | 68.57 | 1.34 |
2 | 72.69 | 1.58 |
3 | 76.54 | 1.69 |
平均 | 72.60 | 1.54 |
批号 | 黄芪总皂苷含量(%) | 黄芪甲苷含量(%) | 得率(%) |
1 | 56.85 | 2.26 | 0.96 |
2 | 57.42 | 2.48 | 1.02 |
3 | 60.58 | 2.89 | 1.12 |
平均 | 58.28 | 2.54 | 1.03 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101726247A CN101011543B (zh) | 2005-12-30 | 2006-12-29 | 一种新的抗肿瘤药物组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510131186 | 2005-12-30 | ||
CN200510131186.5 | 2005-12-30 | ||
CN2006101726247A CN101011543B (zh) | 2005-12-30 | 2006-12-29 | 一种新的抗肿瘤药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101011543A true CN101011543A (zh) | 2007-08-08 |
CN101011543B CN101011543B (zh) | 2010-05-19 |
Family
ID=38699383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101726247A Expired - Fee Related CN101011543B (zh) | 2005-12-30 | 2006-12-29 | 一种新的抗肿瘤药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101011543B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108721532A (zh) * | 2018-09-20 | 2018-11-02 | 上海国宝企业发展中心 | 用于辅助治疗肺癌的中药组合物 |
CN112279860A (zh) * | 2019-07-25 | 2021-01-29 | 贵州柏强制药有限公司 | 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 |
CN115894510A (zh) * | 2022-12-02 | 2023-04-04 | 重庆市中药研究院 | 一种斑蝥素衍生物及其抗肝癌活性应用 |
-
2006
- 2006-12-29 CN CN2006101726247A patent/CN101011543B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108721532A (zh) * | 2018-09-20 | 2018-11-02 | 上海国宝企业发展中心 | 用于辅助治疗肺癌的中药组合物 |
CN112279860A (zh) * | 2019-07-25 | 2021-01-29 | 贵州柏强制药有限公司 | 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 |
CN115894510A (zh) * | 2022-12-02 | 2023-04-04 | 重庆市中药研究院 | 一种斑蝥素衍生物及其抗肝癌活性应用 |
CN115894510B (zh) * | 2022-12-02 | 2024-06-25 | 重庆市中药研究院 | 一种斑蝥素衍生物及其抗肝癌活性应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101011543B (zh) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100548323C (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN101904893B (zh) | 当归补血胶囊的制备方法 | |
CN1985864B (zh) | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 | |
CN100574768C (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
KR20190124197A (ko) | 종양 치료용 한약 조성물 및 그 제조방법 및 응용 | |
CN1981857A (zh) | 由黄芪、红景天和菝葜制成的药物组合物及其制备方法 | |
CN1977885B (zh) | 一种抗肝炎药物组合物 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN100534493C (zh) | 一种新的抗肿瘤复方药物 | |
CN1985873B (zh) | 甘草酸或其盐、人参和黄芪的药物组合物 | |
CN1961898B (zh) | 一种复方半枝莲抗肿瘤药物组合物及其制备方法 | |
CN1954838B (zh) | 一种抗肿瘤的药物组合物 | |
CN1954839B (zh) | 由通关藤、人参和黄芪制成的药物组合物 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1977886B (zh) | 一种由苦参素、灵芝和黄芪制成的药物组合物 | |
CN100493522C (zh) | 一种苦参素和多糖的药物组合物 | |
CN1961894B (zh) | 一种新的复方药物组合物及其制备方法和用途 | |
CN101073611B (zh) | 一种抗肿瘤的药物组合物 | |
CN102813713A (zh) | 一种绵马贯众山楂组合物、其制备方法与应用 | |
CN1961895B (zh) | 一种新的抗癌药物组合物及其制备方法 | |
CN1969937B (zh) | 一种治疗肝炎的药物组合物 | |
CN1970001B (zh) | 一种苦参素、五味子和人参配伍的治疗肝炎的药物组合物 | |
CN101919974B (zh) | 一种治疗神经胶质瘤的中药组合物及其制备方法 | |
CN100584349C (zh) | 一种中西复方药物及其制备方法 | |
CN101049336B (zh) | 一种抗癌药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080516 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080516 Address after: Post encoding No. 2518 block A, Dongchen street, Ji'nan high tech Development Zone in Shandong Province: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Dongchen street, Ji'nan high tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20130930 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130930 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Dongchen street, Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 block A Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: JIANGSU UNIVERSITY OF TECHNOLOGY Free format text: FORMER OWNER: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., LTD. Effective date: 20150105 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 226601 NANTONG, JIANGSU PROVINCE TO: 213001 CHANGZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150105 Address after: 213001 Changzhou Province in the Clock Tower District, Jiangsu, Wu Road, No. 1801 Patentee after: Jiangsu University of Technology Address before: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee before: Haian Su Fu Technology Transfer Center Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20151229 |
|
EXPY | Termination of patent right or utility model |